2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
Adult Acute Monoblastic Leukemia (M5a)
National Cancer Institute (NCI)Small moleculePhase 2Dormant
BBB
74/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 62/ 100
- Competitive Position
- 95/ 100
Competitive context
15 Active assets in the Adult Acute Monoblastic Leukemia (M5a) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ETOPOSIDE Stanford University | Phase 3 | BBB |
Cytosin-Arabinosid Chinese PLA General Hospital | Phase 3 | BBB |
Daunorubicin National Cancer Institute (NCI) | Phase 3 | BBB |
FILGRASTIM Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 3 | BBB |
Cyclophosphamide ECOG-ACRIN Cancer Research Group | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →